Cellevate AB

28/10/2025

Excited to see our CEO Laura Chirica featured in The Pharma Navigator!
In this interview, she shares how our Cellevat3d® nanofiber microcarriers are transforming vaccine manufacturing and unlocking new much needed potential for the industry.

🎥 Watch the full interview here and let’s connect at CPHI Frankfurt to continue the conversation!
https://www.thepharmanavigator.com/news/cphi-frankfurt-2025-unlocking-the-potential-of-3d-cell-cultures-in-vaccine-production-with-novel-nanofiber-platform

Implementation of three-dimensional (3D) cell culture nanofiber systems in industrial vaccine production offers much higher viral vaccine titers, greater scalability and improved process economy, but it will require tight collaboration with the industry to help speed up their wide adoption, stresses

13/10/2025

📢 Cellevate announces major advances in yield and scalability of viral vaccine production with global launch of Cellevat3d® VAX nanofiber microcarriers

Read our latest press release for more information 👉 https://cellevate.com/cellevate-to-announce-major-advances-in-yield-and-scalability-of-viral-vaccine-production-at-world-vaccine-congress-europe-with-global-launch-of-cellevat3d-vax-nanofiber-microcarriers/

Key highlights:
✅ >13-fold higher infectious viral vaccine titers in Vero cell cultures compared to industry-standard microcarriers
✅ 11.4-fold higher infectious enterovirus vaccine titers demonstrated in HEK293T cultures in an independent study conducted by Intravacc B.V. (CDMO, The Netherlands)
✅ Formation of homogeneous, high-density 3D spheroid cultures, supporting efficient virus propagation, high cell-specific viral productivity and scale-up
✅ 85% reduction in cost of production for viral vaccine processes compared to current industry-standard

“With this new product launch, Cellevate demonstrates the versatility of its next-generation, nanofiber-based microcarrier platform across all areas of adherent cell cultivation. Breakthrough medicine requires breakthrough innovations in biomanufacturing and Cellevate will keep delivering on that paradigm.”
— Dr. Uwe Gottschalk, Chairman of the Board, Cellevate

10/10/2025

🚀Cellevate launches new nanofiber product for vaccine production next week!

Cellevat3d® VAX nanofiber microcarriers provide more than 10-fold increase in viral vaccine titers. See you at World Vaccine Congress Europe in Amsterdam, Oct 14–16! ✨

Launch presentation: Manufacturing Technologies Track, October 16, at 12.30 presented by Dr. Christel Fenge, CTO Cellevate.

📍 Connect with us on site, Laura Chirica, PhD, CEO and Dr. Christel Fenge, CTO

17/09/2025

✨Cellevate at CPHI in Frankfurt, October 28–30!
Laura Chirica, PhD (CEO) and Bettina Berendsen (Strategic Advisor & Board Member) will be on-site at CPHI to simply meet and discuss how Cellevat3d® nanofibers can help to eliminate cell culture bottlenecks in biomanufacturing. Let’s talk about Cellevat3d® VAX nanofibers for vaccine production!

🌟 Key benefits:
✅ Up to 14-fold higher yields vs. current processes
✅ Easy scale-up
✅ Faster bioprocessing and enhanced productivity
✅ High quality
✅ Reduced waste and water use
✅ Improved production economy

🚀 Don’t miss the global launch of Cellevat3d® VAX nanofiber microcarriers at the World Vaccine Congress Europe in Amsterdam, October 14-16, 2025.

📍 Let’s connect at CPHI - reach out to schedule a meeting!

19/08/2025

🚀 More than 10-fold increase in viral vaccine production titers with Cellevat3d® nanofiber microcarriers!

Today, we are excited to share results from Cellevate’s vaccine production validation program dedicated to evaluating cell culture products based on our proprietary nanotechnology Cellevat3d®.

🔬 Key highlights:
• Dense and uniform 3D spheroid formation with Vero cells
• High infectious titers of enterovirus A71 (EV71) successfully produced in nanofiber-based cultures
• Independent benchmarking by Intravacc (CDMO, NL) showed:
✨ 11.4-fold increase in infectious virus titers
✨ 17-fold improvement in cell-specific virus yield

These results underline the ability of Cellevat3d® to dramatically enhance vaccine manufacturing, with the potential of cutting production costs by up to 85% while boosting scalability and sustainability.

The Cellevat3d® VAX nanofiber microcarriers will be launched at World Vaccine Congress Europe in Amsterdam, October 13-16 2025.

📄 A full summary of the performance data is available in our new Application Note.

👉 Read more in our press release and download the Application Note.
https://cellevate.com/more-than-10-fold-enhanced-viral-vaccine-production-titers-using-the-novel-cellevat3d-nanofiber-microcarriers/